Floatz logo

Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Chimeric Antigen Receptor Modified T Cells Infusion
HER2 Positive Breast Carcinoma
National University Hospital, SingaporeP1/2CCC (48)
Chimeric Antigen Receptor Modified T Cells Infusion
Pancreas Cancer
Second Affiliated Hospital of Guangzhou Medical UniversityP1/2CCC (48)
Chimeric Antigen Receptor Modified T Cells Infusion
Plasmacytoma
Shenzhen Geno-Immune Medical InstituteP1/2CCC (48)
Chimeric Antigen Receptor Modified T Cells Infusion
T-lymphocyte Lymphoma
Tianjin Medical University General HospitalP1/2CCC (48)
Claudin18.2 Car-T Cells
Exocrine Pancreatic Carcinoma
Essen BiotechP1/2CCC (48)
cll1/+cd33 car-t
AML
Shenzhen Geno-Immune Medical InstituteP1/2CCC (48)
Clls52
B-Cell Non-Hodgkin Lymphoma
Cellectis S.A.P1/2CCC (48)
ct071
Plasma Cell Leukemia
CARsgen Therapeutics Co., Ltd.P1/2CCC (48)
ctd402 car t cell
T-Cell Acute Lymphoblastic Leukemia
BIOHENG THERAPEUTICS US LLCP1/2CCC (48)
ctd402 car t cell
Lymphoblastic Lymphoma
BIOHENG THERAPEUTICS US LLCP1/2CCC (48)
Cytokine-Treated Veto Cells
Aplastic Anemia
M.D. Anderson Cancer CenterP1/2CCC (48)
Cytokine-Treated Veto Cells
Bone Marrow Failure Syndrome
M.D. Anderson Cancer CenterP1/2CCC (48)
Cytokine-Treated Veto Cells
Chronic Myeloid Leukemia
M.D. Anderson Cancer CenterP1/2CCC (48)
Cytokine-Treated Veto Cells
Plasma Cell Myeloma
M.D. Anderson Cancer CenterP1/2CCC (48)
Dc-Cik
Cholangiocarcinoma
M.D. Anderson Cancer CenterP1/2CCC (48)
Dc-Cik
High-risk Soft Tissue Sarcoma
Affiliated Hospital to Academy of Military Medical SciencesP1/2CCC (48)
doc1021
Melanoma
Diakonos Oncology CorporationP1/2CCC (48)
Donor-Derived Ex-Vivo Expanded Ebv Tscm Ctl
Epstein-Barr Virus-Associated Lymphoproliferative Disorder
University Hospital, Basel, SwitzerlandP1/2CCC (48)
Donor-Derived Ex-Vivo Expanded Ebv Tscm Ctl
Post-Transplant Lymphoproliferative Disease
University Hospital, Basel, SwitzerlandP1/2CCC (48)
Dualcar-Nk19/70 Cell
B-Cell Non-Hodgkin Lymphoma
Aibin Liang，MD，Ph.D.P1/2CCC (48)
Dual-Target Antigen-Selected Car-Nk
Prostate Cancer
Essen BiotechP1/2CCC (48)
Dual-Target Car-Nk Cell Product
Recurrent or Refractory Disease After Standard Therapies
Beijing BiotechP1/2CCC (48)
Dual-Target Car-Nk Cells
Cancer
Beijing BiotechP1/2CCC (48)
Dual-Target Car-Nk Cells
Breast Cancer
Beijing BiotechP1/2CCC (48)
eb103
B-Cell Non-Hodgkin Lymphoma
Estrella Biopharma, Inc.P1/2CCC (48)
Showing 726 to 750 of 3,774 assets
PreviousPage 30 of 151Next